Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CNECT-VAX

Financiado

C- and N-terminal Epitope Conjugate immune Cell Targeted Vaccines

CNECT-VAX will validate the technical and commercial feasibility of a new cancer vaccine platform that uses nanobodies targeting dendritic cells to co-deliver antigens in vivo. As of 2019, cancer affects over 19 million people wor... ver más

30/11/2023

RADBOUDUMC

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-30

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

RADBOUDUMC

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

JCI-2008-3205 Novel Approaches in Cancer Therapy: Conjugation of Tumor-Der... 101K€ Cerrado

SAF2014-53563-REDT RED DE INMUNOTERAPIA DEL CANCER 32K€ Cerrado

PCIN-2016-025 NANOVACUNAS DISEÑADAS PARA INMUNOTERAPIA ANTITUMORAL 100K€ Cerrado

SAF2016-81937-REDT RED DE INMUNOTERAPIA DEL CANCER 20K€ Cerrado

RYC2021-033381-I Immunotherapeutic strategies to improve NK cell-based cancer... 236K€ Cerrado

PID2020-117544RB-I00 NANOBOMBA TERMOFORETICA DIRIGIDA Y CELULAS CAR MONITORIZADAS... 171K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-05-05
Fecha Fin: 2023-11-30

Líder del proyecto

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto CNECT-VAX will validate the technical and commercial feasibility of a new cancer vaccine platform that uses nanobodies targeting dendritic cells to co-deliver antigens in vivo. As of 2019, cancer affects over 19 million people worldwide and results in almost 10 million death annually, however, the treatment of patients remains a challenge. Immunotherapy options including dendritic cell (DC) based vaccines have become available, but the clinical efficacy of such treatment remains very modest and restricted to patient subsets. To overcome the limitations in the current state-of-art solutions and break barriers to achieve higher clinical efficacy, Dr. Martijn Verdoes proposes a novel molecular vaccine strategy that effectively delivers target antigens to DCs in vivo in the patient to concomitantly induce robust synergistic CD4+ and CD8+ T cell responses. The technical feasibility of CNECT-VAX will be assessed both in vitro and in vivo, using monocyte-derived human dendritic cells (MoDC) and a mouse model containing humanized DCs respectively. In both systems, the functionality of DCs and the consequent T cell activation and immune responses will be measured. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CNECT-VAX could reduce the profound socioeconomic burden of cancer, extend and improve the lives of patients, provide the pharmaceutical industry with further collaborative opportunities, and stimulate further scientific research based on this platform to treat other pathogenic diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores